Plasma P-tau2017 and Quantitative Amyloid PET Imaging in a Cognitively Normal Population
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Invicro
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Creation of a database of brain amyloid deposition by region using PET signal-to-noise ratio, SUVr .
研究概览
简要总结
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels.
详细描述
The overall goal of this protocol is to compare amyloid burden assessed by amyloid PET to plasma P-tau217 levels. Other relevant AD-related investigational biomarkers may also be assessed in the provided samples. Apolipoprotein E (ApoE) genetic status will be evaluated with a serum sample.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
[18F]Florbetapir
Participants will undergo amyloid PET imaging with an approved amyloid radiotracer (ie, [18F]Florbetapir (Amyvid™)) to assess β-amyloid neuritic plaque density.
干预措施: Amyvid (Drug)
结局指标
主要结局
Creation of a database of brain amyloid deposition by region using PET signal-to-noise ratio, SUVr .
时间窗: 1 year
Amyloid PET imaging will be used to measure regional brain amyloid deposition in each subject.
次要结局
- Creation of a database of blood P-tau217 and other blood biomarkers.(1 year)